SCHEMBL5071460

SCHEMBL5071460

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.63
NR1H3 Q13133 1/20 0.51
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
C5AR1 P21730 1/20 0.49
PDE4B Q07343 2/20 0.48
MAPT P10636 2/20 0.46
MEN1 O00255 2/20 0.46
CYP1A2 P05177 2/20 0.46
KMT2A Q03164 2/20 0.46
HSD11B1 P28845 2/20 0.45
TP53 P04637 2/20 0.45
ADORA2B P29275 2/20 0.42
TLR8 Q9NR97 1/20 0.42
GPR84 Q9NQS5 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18152846 0.86 TSHR (0.61) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL18152809 0.85 TSHR (0.65) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL648785 0.82 TSHR (0.56) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL1912807 0.81 TSHR (0.55) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL650694 0.81 TSHR (0.51) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL8843875 0.80 TSHR (0.54) TSHRPDE4BMEN1CYP1A2KMT2A
SCHEMBL6619406 0.80 TSHR (0.58) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL651094 0.80 TSHR (0.50) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL11213223 0.79 TSHR (0.57) TSHRNR1H3KDM4EALDH1A1HPGD
SCHEMBL8103682 0.79 TSHR (0.53) TSHRPDE4BMEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed